Display options
Cite
Grant WB. Critique of the U-shaped serum 25-hydroxyvitamin D level-disease response relation. Dermatoendocrinol. 2009;1(6):289-93doi: 10.4161/derm.1.6.11359.
Grant, W. B. (2009). Critique of the U-shaped serum 25-hydroxyvitamin D level-disease response relation. Dermato-endocrinology, 1(6), 289-93. https://doi.org/10.4161/derm.1.6.11359
Grant, William B. "Critique of the U-shaped serum 25-hydroxyvitamin D level-disease response relation." Dermato-endocrinology vol. 1,6 (2009): 289-93. doi: https://doi.org/10.4161/derm.1.6.11359
Grant WB. Critique of the U-shaped serum 25-hydroxyvitamin D level-disease response relation. Dermatoendocrinol. 2009 Nov;1(6):289-93. doi: 10.4161/derm.1.6.11359. PMID: 21572873; PMCID: PMC3092568.
Copy Download .nbib Format: NLM
Share it on

Dermatoendocrinol. 2009 Nov;1(6):289-93. doi: 10.4161/derm.1.6.11359.

Critique of the U-shaped serum 25-hydroxyvitamin D level-disease response relation.

Dermato-endocrinology

William B Grant

Affiliations

  1. Sunlight, Nutrition and Health Research Center (SUNARC); San Francisco, CA USA.

PMID: 21572873 PMCID: PMC3092568 DOI: 10.4161/derm.1.6.11359

Abstract

Previous work has suggested an optimal serum 25-hydroxyvitamin D [25(OH)D] level near 20-30 ng/mL, above which disease risk may increase. Although based primarily on a prostate cancer study in Nordic countries, examples include esophageal, and pancreatic cancer, cardiovascular disease, and all-cause mortality rate. However, these studies apparently are not representative of the findings in the literature for these diseases or disease outcome in general. The prostate cancer study was from Nordic countries and used serum 25(OH)D levels from more than 15 years prior to cancer diagnosis for about half of the cases. Most studies of prediagnostic serum 25(OH)D find no significant correlation with risk of prostate cancer. Many risk-modifying factors for prostate cancer exist that observational studies generally do not include. The esophageal cancer data were from a region of China with high incidence of esophageal cancer. The pancreatic study was conducted on smokers in Finland. Both the esophageal and pancreatic studies are at odds with many ecological and observational studies in various countries. When several studies for cardiovascular disease, and all-cause mortality rate are combined in preliminary meta-analyses, the best fits to the data show a monotonic decrease of hazard ratio with increasing logarithm of serum 25(OH)D. Thus, little support exists for the U-shaped serum 25(OH)D level-disease response relation, and the few studies that do should not be used in forming public health policies regarding vitamin D and ultraviolet-B irradiance.

Keywords: 25-hydroxyvitamin D; all-cause mortality rate; cardiovascular disease; esophageal cancer; pancreatic cancer; prostate cancer; vitamin D

References

  1. Arch Intern Med. 2008 Jun 9;168(11):1174-80 - PubMed
  2. Anticancer Res. 2010 Jan;30(1):189-99 - PubMed
  3. Int J Cancer. 2010 Jul 1;127(1):93-100 - PubMed
  4. Nutr Rev. 2008 Oct;66(10 Suppl 2):S147-52 - PubMed
  5. J Steroid Biochem Mol Biol. 2009 Mar;114(1-2):78-84 - PubMed
  6. Dermatoendocrinol. 2009 Jan;1(1):17-24 - PubMed
  7. Cancer Epidemiol. 2009 Dec;33(6):435-45 - PubMed
  8. Int J Cancer. 2009 Feb 15;124(4):979-86 - PubMed
  9. Eur Urol. 2004 Mar;45(3):271-9 - PubMed
  10. Dermatoendocrinol. 2009 Jul;1(4):207-14 - PubMed
  11. Prog Biophys Mol Biol. 2009 Feb-Apr;99(2-3):104-13 - PubMed
  12. Br J Cancer. 2007 Jul 2;97(1):123-8 - PubMed
  13. Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2784-6 - PubMed
  14. Anticancer Res. 2006 Jul-Aug;26(4A):2687-99 - PubMed
  15. Cancer Res. 2009 Feb 15;69(4):1439-47 - PubMed
  16. Altern Med Rev. 2008 Mar;13(1):6-20 - PubMed
  17. Maturitas. 2010 Mar;65(3):225-36 - PubMed
  18. Int J Cancer. 2007 Mar 1;120(5):1123-8 - PubMed
  19. Dermatoendocrinol. 2009 Jan;1(1):25-33 - PubMed
  20. Mol Nutr Food Res. 2010 Aug;54(8):1172-81 - PubMed
  21. Arch Intern Med. 2008 Aug 11;168(15):1629-37 - PubMed
  22. Proc R Soc Med. 1965 May;58:295-300 - PubMed
  23. Am J Clin Nutr. 2007 Jun;85(6):1586-91 - PubMed
  24. Asian Pac J Cancer Prev. 2007 Apr-Jun;8(2):236-42 - PubMed
  25. Photochem Photobiol. 2008 Mar-Apr;84(2):356-65 - PubMed
  26. Sci Am. 1996 Jul;275(1):52-3, 56-9 - PubMed
  27. J Steroid Biochem Mol Biol. 2010 Feb 15;118(3):162-70 - PubMed
  28. Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16351-6 - PubMed
  29. Psychoneuroendocrinology. 2009 Dec;34 Suppl 1:S278-86 - PubMed
  30. Cancer. 2002 Mar 15;94(6):1867-75 - PubMed
  31. Pancreas. 2009 May;38(4):387-90 - PubMed
  32. Cancer Causes Control. 2000 Oct;11(9):847-52 - PubMed
  33. Int J Cancer. 2004 Sep 1;111(3):470-1; author reply 472 - PubMed
  34. Int J Health Geogr. 2007 Jul 26;6:34 - PubMed
  35. Arch Intern Med. 2008 Jun 23;168(12):1340-9 - PubMed
  36. Prostate Cancer Prostatic Dis. 2009;12(3):215-26 - PubMed
  37. Cancer Res. 2006 Oct 15;66(20):10213-9 - PubMed
  38. Eur J Clin Nutr. 2010 Feb;64(2):203-9 - PubMed
  39. Jpn J Clin Oncol. 1985 Jun;15(2):403-13 - PubMed
  40. Am J Epidemiol. 2009 Oct 15;170(8):1032-9 - PubMed
  41. Anticancer Res. 2009 Sep;29(9):3675-84 - PubMed
  42. BMC Cancer. 2006 Nov 10;6:264 - PubMed
  43. Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1688-95 - PubMed
  44. J Am Geriatr Soc. 2009 Sep;57(9):1595-603 - PubMed
  45. Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1889-93 - PubMed
  46. Urology. 2008 Mar;71(3):531-5 - PubMed
  47. Int J Cancer. 2005 Jan 20;113(3):456-63 - PubMed
  48. Health Phys. 2004 Nov;87(5):532-8 - PubMed
  49. Photochem Photobiol. 2005 Nov-Dec;81(6):1276-86 - PubMed
  50. Circulation. 2008 Jan 29;117(4):503-11 - PubMed
  51. Int J Cancer. 2004 Jan 1;108(1):104-8 - PubMed

Publication Types